Weight-loss drugs drove a 13.6% increase in prescription medication spending in the United States in 2023, according to a report from the American Society of Health-System Pharmacists (ASHP) published Wednesday (April 24). The report says spending on those drugs will likely increase as supply catches up to demand, and in 2024, specialty, endocrine and cancer drugs will also drive expenditures. According to ASHP, spending on semaglutide, for weight-loss and diabetes, doubled and on tirzepatide, for weight-loss and diabetes, grew by...